BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 11166288)

  • 1. Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
    Hadj Tahar A; Ekesbo A; Grégoire L; Bangassoro E; Svensson KA; Tedroff J; Bédard PJ
    Eur J Pharmacol; 2001 Feb; 412(3):247-54. PubMed ID: 11166288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys.
    Hadj Tahar A; Bélanger N; Bangassoro E; Grégoire L; Bédard PJ
    Eur J Pharmacol; 2000 Jul; 399(2-3):183-6. PubMed ID: 10884518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys.
    Hadj Tahar A; Grégoire L; Bangassoro E; Bédard PJ
    Clin Neuropharmacol; 2000; 23(4):195-202. PubMed ID: 11020123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    Riahi G; Morissette M; Parent M; Di Paolo T
    Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
    Morissette M; Samadi P; Hadj Tahar A; Bélanger N; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):446-54. PubMed ID: 20026151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
    Johnston TH; Geva M; Steiner L; Orbach A; Papapetropoulos S; Savola JM; Reynolds IJ; Ravenscroft P; Hill M; Fox SH; Brotchie JM; Laufer R; Hayden MR
    Mov Disord; 2019 May; 34(5):708-716. PubMed ID: 30575996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias.
    Ouattara B; Belkhir S; Morissette M; Dridi M; Samadi P; Grégoire L; Meltzer LT; Di Paolo T
    J Mol Neurosci; 2009 Jun; 38(2):128-42. PubMed ID: 18704766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
    Bélanger N; Grégoire L; Bédard PJ; Di Paolo T
    Neurobiol Aging; 2006 Nov; 27(11):1684-93. PubMed ID: 16253392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():27-38. PubMed ID: 25046277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
    Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Mov Disord; 2006 Jan; 21(1):9-17. PubMed ID: 16127720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys.
    Grondin R; Hadj Tahar A; Doan VD; Ladure P; Bédard PJ
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Feb; 361(2):181-6. PubMed ID: 10685874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Curr Neuropharmacol; 2016; 14(5):481-93. PubMed ID: 26639458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.